Abstract
Objective: To evaluate the efficacy, safety, pain, and quality of life associated with the use of adalimumab, clindamycin, and/or rifampicin in the treatment of hidradenitis suppurativa. Methods: Prospective and retrospective cohort studies, randomized clinical trials and equivalence studies, and economic analyses, conducted in adults diagnosed with hidradenitis suppurativa who have used at least one of the following therapeutic alternatives: adalimumab, clindamycin, or rifampicin, will be included. Studies should address one or more outcomes such as abscess and/or nodule counts, presence of inflammatory nodules, pain levels, quality of life, safety, and cost. Databases consulted will include Medical Literature Analysis and Retrieval System Online (MEDLINE, OVID interface), Excerpta Medica DataBASE (EMBASE), Latin American and Caribbean Literature in Health Sciences (LILACS), Cumulative Index to Nursing and Allied Health Literature (CINAHL, EBSCO interface), Psychological Abstracts (PsycINFO, EBSCO interface), Web of Science (WoS), and Source-Neutral Abstract and Citation Database (Scopus). Screening, selection, and extraction processes will be conducted by independent and previously trained researchers. Risk of bias will be assessed using the Risk of Bias 2.0 and ROBINS-I tools. Results will be summarized in a qualitative and quantitative synthesis, including specificity and subgroup analyses.
References
Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. Dermatology. 2020;236(5):393-412. https://doi.org/10.1159/000507323
Alikhan A, Sayed C, Alayi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurative Foundations. J Am Acad Dermatol. 2019;81(1). https://doi.org/10.1016/j.jaad.2019.02.067
Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2021;237(1):81-96. https://doi.org/10.1159/000503605
Ghanian S, Takaichi MY, Naik HB, Alavi A. Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What’s New? Am J Clin Dermatol. 2022;23(2). https://doi.org/10.1007/s40257-021-00667-8
Ochi H, Tan LC, Oon HH. The effect of oral clindamycin and rifampicin combination therapy in patients with hidradenitis suppurativa in Singapore. Clin Cosmet Investig Dermatol. 2018;11. https://doi.org/10.2147/CCID.S136730
Magalhães RF, Rivitti-Machado MC, Duarte GV, Souto R, Nunes DH, Chaves M, et al. Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94. https://doi.org/10.1590/abd1806-4841.20198607
Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah. VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand. Curr Med Res Opin. 2019;35(10). https://doi.org/10.1080/03007995.2019.1634952
Ghanian S, Yamanaka-Takaichi M, Naik HB, Alavi A. Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New? Am J Clin Dermatol. 2022 Mar;23(2):167-176. https://doi.org/10.1007/s40257-021-00667-8
Lu JW, Huang YW, Chen TL. Efficacy and safety of adalimumab in hidradenitis suppurativa. Medicine (Baltimore). 2021;100(22). https://doi.org/10.1097/MD.0000000000026190
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.
Sataloff RT, Bush ML, Chandra R, Chepeha D, Rotenberg B, Fisher EW, et al. Systematic and other reviews: criteria and complexities. J Otolaryngol. 2021;50(41). https://doi.org/10.1186/s40463-021-00527-9
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71). https://doi.org/10.1136/bmj.n71
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Array